The increased expression of inflammatory genes in inflammatory lung diseases is regulated by acetylation of core histones, whereas histone deacetylase-2 (HDAC2) suppresses inflammatory gene expression. Corticosteroids suppress inflammatory genes in asthma by inhibiting histone acetyltransferase and in particular by recruiting HDAC2 to the nuclear factor-kB-activated inflammatory gene complex. This involves deacetylation of the acetylated glucocorticoid receptor. In COPD, severe asthma and asthmatics who smoke, HDAC2 is reduced, thus preventing corticosteroids from suppressing inflammation. The reduction in HDAC2 appears to be secondary to increased oxidative and nitrative stress in the lungs. Antioxidants and inhibitors of nitric oxide synthesis may therefore restore corticosteroid sensitivity in COPD, but this can also be achieved by low concentrations of theophylline and curcumin, which act as HDAC activators. Theophylline is a direct inhibitor of oxidant-activated phosphoinositide-3-kinase-d, which is involved in inactivation of HDAC2. In the future selective PI3Kd inhibitors and more direct activators of HDAC2 may be used to treat corticosteroid-resistant inflammatory diseases of the lung, including COPD, severe asthma and asthma in smokers.
Introduction
Histone deacetylases (HDAC) play a critical role in gene suppression through the recruitment of co-repressor proteins to switch off gene transcription, which is activated by histone acetylation. Activated inflammatory genes are suppressed by HDAC2 and since corticosteroids recruit HDAC2 to switch off multiple inflammatory genes, this has suggested that targeting HDAC2 may be a novel target for the development of new anti-inflammatory treatments, particularly in diseases where there is active corticosteroid resistance. This review discusses the role of HDAC2 in airway disease and how this can be used to develop new treatments, especially in chronic obstructive pulmonary disease (COPD) and refractory asthma.
Histone acetylation and deacetylation
Gene expression is regulated by acetylation of core histones which open up the chromatin structure (chromatin remodelling) to allow transcription factors and RNA polymerase to bind to DNA, thus initiating gene transcription [Szyf, 2009; Kouzarides, 2007; Shahbazian and Grunstein, 2007] . Gene expression is regulated by various coactivator molecules, such as CREBbinding protein and p300, all of which have intrinsic histone acetyltransferase (HAT) activity. Expression of inflammatory genes is regulated by increased acetylation of histone-4 Ito et al. 2000 ]. Thus epigenetic factors play a critical role in chronic inflammation [Adcock et al. 2006 ].
In asthma patients there is evidence for increased acetylation of histone-4, consistent with increased expression of multiple inflammatory genes [Ito et al. 2002a] . Many of these genes are regulated by the transcription factor nuclear factor-kB (NF-kB) which may also be acetylated. In COPD, peripheral lung, airway biopsies and alveolar macrophages there is an increase in the acetylation of histones associated with the promoter region of inflammatory genes, such as CXCL8 (interleukin-8) that are regulated by NF-kB and the degree of acetylation increases with disease severity ]. This increased acetylation of histones associated with inflammatory genes is not due to an increase in HAT activity in lungs or macrophages as in asthma, but due to decreased HDAC activity. Histone acetylation is reversed by HDACs and there are 11 HDAC isoenzymes that deacetylate histones and other proteins within the nucleus [Thiagalingam et al. 2003 ]. Specific HDACs appear to be differentially regulated and to regulate different groups of genes. HDACs play a critical role in the suppression of gene expression by reversing the hyperacetylation of core histones. For the regulation of inflammatory genes HDAC2 appears to be critical importance Ito et al. 2000 ]. The role of other HDACs in inflammatory diseases is far less certain, but HDAC1 is often associated with HDAC2 in the nucleus, although it does not appear to be involved directly with the regulation of inflammatory genes or the antiinflammatory actions of corticosteroids. The expression of inflammatory genes is determined by a balance between histone acetylation (which activates transcription) and deacetylation which switches off transcription.
It has been increasingly recognized that many regulatory proteins, particularly transcription factors and nuclear receptors, are also regulated by acetylation that is controlled by HATs and HDACs [Popov et al. 2007 ]. Acetylation plays a key role in the regulation of androgen and estrogen receptors, and this is also the case for glucocorticoid receptors (GRs) ]. The GR is acetylated within the nucleus at specific lysine residues close to the hinge region of the receptor and only binds to its DNA binding site in its acetylated form. However, in order to inhibit NF-kB-activated genes it is necessary to deacetylate the receptor and this is achieved by HDAC2 ( Figure 1) . Binding of the GR to DNA requires acetylation of the receptor, so any increase in GR acetylation may lead to gene activation, including genes that mediate the metabolic and endocrine side effects of corticosteroids.
HDAC2 in lung disease
HDAC2 in COPD HDAC activity is reduced in alveolar macrophages of cigarette smokers compared with nonsmokers and this is correlated with increased expression of inflammatory genes in these cells [Barnes, 2009a; Ito et al. 2001] . There is also a reduction in total HDAC activity in peripheral lung, bronchial biopsies and alveolar macrophages from COPD patients and this is correlated with disease severity and with increased gene expression of CXCL8 and increased Inflammatory genes GM-CSF, IL-8 "Side effect" genes e.g. osteocalcin "Anti-inflammatory" genes e.g. MKP-1 Figure 1 . Acetylation of the glucocorticoid receptor (GR). After corticosteroid binding to the GR the receptor translocates to the nucleus where it is acetylated by a histone acetyltransferase (HAT), which is necessary for the GR to bind to its glucocorticoid receptor recognition element (GRE) in the promoter region of steroidsensitive genes, which include the genes that mediate the side effects of corticosteroids, such as osteocalcin. It is necessary for the acetylated GR to be deacetylated by histone deacetylase 2 (HDAC2) in order to inhibit activated nuclear factor-kB (NF-kB) to suppress activated inflammatory genes.
acetylation of histone associated with the NF-kB binding site on the CXCL8 promoter [Szulakowski et al. 2006; Ito et al. 2005 ]. There is a selective reduction in the expression of HDAC2, with lesser reductions in HDAC3 and HDAC5. In patients with very severe COPD (GOLD stage 4) the expression of HDAC2 was less than 5% of that seen in normal lung. In parallel with the reduced protein expression of HDAC2 there was also a reduction in its messenger RNA, suggesting that there may be a reduction in transcription of the HDAC2 gene or a reduced stability of its mRNA. However, almost nothing is known about the transcriptional regulation of HDAC genes and this is an area of current research activity.
HDAC2 is reduced in alveolar macrophages from COPD patients to a greater extent than in macrophages from individuals with normal lung function and this is correlated with corticosteroids insensitivity. Restoration of HDAC2 expression to normal by transfection with a plasmid vector of HDAC2 reverses corticosteroid resistance in these cells, whereas transfection with an HDAC1 vector is without effect ]. This provides compelling evidence that the reduction in HDAC2 seen in COPD is linked to reduce corticosteroid responsiveness.
As discussed above, HDAC2 is required for the deacetylation activated nuclear GR in order for GR to inhibit NF-kB activity and therefore the expression of inflammatory genes. The reduced activity of HDAC2 in COPD patients is associated with increased acetylation of GR, which may be a major mechanism accounting for corticosteroid resistance in COPD ]. In addition, the increased acetylated GR may promote gene activation and gene suppression by binding to GR recognition sequences in steroid-sensitive genes, such as genes involved in side effects of corticosteroids (e.g. osteocalcin, which is involved in osteoporosis, pro-opiomelanocortin and suppression of the hypothalamopituitaryadrenal axis) The reduced HDAC2 in COPD may therefore lead not only to amplified inflammation and corticosteroid resistance, but may also increase the risk of corticosteroidinduced side effects.
HDAC2 in asthma
In patients with mild asthma there is a small reduction in HDAC2 activity in bronchial biopsies and alveolar macrophages, but HDAC2 activity is reduced to a greater extent in patients with severe asthma and in asthmatics who smoke [Bhavsar et al. 2008; Ito et al. 2002a ]. The reduction in HDAC2 activity in patients with mild asthma is restored by treatment with inhaled corticosteroids [Ito et al. 2002a ]. HDAC activity is also reduced in peripheral blood mononuclear cells (PBMC) of patients with severe asthma and this is correlated with resistance to the antiinflammatory effects of corticosteroids in vitro [Hew et al. 2006 ].
HDAC2 in other lung diseases
Peripheral lung tissue from patients with cystic fibrosis and interstitial pulmonary fibrosis has normal HDAC2 expression and activity ]. However, the role of HDAC2 in these diseases has not been carefully investigated and our preliminary data suggest that HDAC2 is reduced in sputum macrophages and PBMC of patients with cystic fibrosis.
Corticosteroids suppress inflammation via HDAC2
There have been major advances in understanding the molecular mechanisms whereby glucocorticoids suppress inflammation, which also provides important insights into how corticosteroid-resistance may arise [Barnes and Adcock, 2009; Barnes, 2006a] . A major mechanism of action of corticosteroids involves changes in histone acetylation to regulate inflammatory and anti-inflammatory genes. Corticosteroids diffuse across the cell membrane and bind to GRs in the cytoplasm. Upon ligand binding, GRs are activated and released from chaperone proteins (heat shock protein 90 and others) and rapidly translocate to the nucleus where they exert their molecular effects through the activation and suppression of multiple genes involved in the inflammatory process. GRs homodimerize and bind to glucocorticoid response elements (GRE) in the promoter region of glucocorticoid-responsive genes and this interaction switches on (or occasionally switches off) gene transcription. Genes that are switched on by glucocorticoids include genes encoding b 2 -adrenergic receptors and the anti-inflammatory proteins secretory leukoprotease inhibitor and mitogen-activated protein kinase phosphatase-1 (MKP-1), which inhibits MAP kinase pathways. However, the major action of corticosteroids is to switch off multiple activated inflammatory genes that encode for cytokines, chemokines, adhesion molecules inflammatory enzymes and receptors, which are regulated by proinflammatory transcription factors, such as NF-kB and activator protein-1 (AP-1) These transcription factors activate inflammatory genes through histone acetylation, whereas activated GRs reverse this process by interacting with co-repressor molecules to attenuate NF-kB-associated coactivator activity, thus reducing histone acetylation [Barnes, 2006a; Ito et al. 2000 ]. Reduction of histone acetylation mainly occurs through the specific recruitment of HDAC2 to the activated inflammatory gene complex by activated GR, thereby resulting in effective suppression of activated inflammatory genes within the nucleus. GR becomes acetylated upon ligand binding allowing it to bind to GREs and HDAC2 can target acetylated GR thereby allowing it to associate with the NF-kB complex ] (Figure 1 ).
Corticosteroid resistance in lung disease
Corticosteroid resistance is an important characteristic in COPD patients, but is also important in severe asthma and in asthma in smokers [Barnes and Adcock, 2009; Adcock and Barnes, 2008] . Since an important molecular mechanism for the anti-inflammatory action of corticosteroids is the recruitment by ligand-bound GR of HDAC2 to activated inflammatory genes, thus reversing the acetylation of these inflammatory genes and silencing of their transcription [Barnes, 2006a; Barnes and Adcock, 2003; Ito et al. 2000 ]. In patients with COPD the reduction in HDAC2 expression may thus account for the corticosteroid insensitivity which is seen in this disease . Corticosteroids provide little clinical benefit in COPD patients and fail to significantly reduce progression of the disease or to reduce its mortality [Suissa and Barnes, 2009; Yang et al. 2007; Calverley et al. 2007 ]. This may reflect the fact that corticosteroids, even in high systemic doses, do not suppress inflammation in the lungs, in marked contrast to their high level of efficacy in asthma [Loppow et al. 2001; Culpitt et al. 1999; Keatings et al. 1997 ] and fail to suppress the secretion of inflammatory proteins, such as CXCL8 and matrix metalloproteinase-9, from macrophages [Culpitt et al. 2003; Russell et al. 2002] . The reduction in HDAC2 expression in COPD cells may therefore not only account for the amplification of inflammation, but also the insensitivity to the anti-inflammatory effects of corticosteroids [Barnes, 2009a [Barnes, , 2006a (Figure 2) .
Patients with severe asthma also have reduced responsiveness to corticosteroids, and this may be manifest in circulating PBMCs as well as in alveolar macrophages [Bhavsar et al. 2008; Hew et al. 2006; Matthews et al. 2004 ]. Reduced HDAC2 activity accounts for this corticosteroids resistance at least in part, although other molecular mechanisms have also been described . Smoking asthmatics are also relatively resistant to the anti-inflammatory effects of corticosteroids and this makes them more difficult to control than nonsmoking asthmatics [Chaudhuri et al. 2006 ]. Cigarette smoking is an oxidative stress so it is likely that similar mechanisms through a reduction in HDAC2 activity apply [Ahmad et al. 2008] .
Mechanisms of HDAC reduction
The reasons for the reduction in HDAC, particularly HDAC2, in COPD and severe/smoking asthma are not yet completely understood. However, there is increasing evidence that this may be due to inactivation of the enzyme by oxidative and nitrative stress Rahman et al. 2004] (Figure 3 ). Oxidative stress is increased in COPD and increases with disease severity [Bowler et al. 2004; Montuschi et al. 2000; Paredi et al. 2000 ]. Nitrative stress is also increased in the peripheral lung of COPD patients [Brindicci et al. 2005] and there is increased expression of inducible nitric oxide synthase (iNOS) in small airways and the lung parenchyma [Ricciardolo et al. 2005 ]. Oxidative stress is also increased in severe and smoking asthma [Paredi et al. 2002; Montuschi et al. 1999 ]. Oxidative and nitrative stress lead to the rapid formation of peroxynitrite, which is increased in exhaled breath condensate of patients with COPD [Osoata et al. 2009b ].
Peroxynitrite nitrates selected tyrosine residues on certain proteins. HDAC2, but not other isoforms of HDAC, shows increased tyrosine nitration in macrophages and peripheral lung of COPD patients and this is correlated with increased expression of CXCL8 ]. Oxidative and nitrative stress induce corticosteroid resistance in macrophage-like cells (U937 cells) in vitro and this is mimicked by cigarette smoke extract and reversed by the antioxidant N-acetylcysteine. In vivo exposure of mice to cigarette smoke reduces HDAC activity in the lungs and induces a steroid-resistant neutrophilic inflammation [Fox et al. 2007; Marwick et al. 2004 ]. Nitration of HDAC2 not only inactivates the catalytic activity of this enzyme, but also leads to its ubiquitination, which marks it for degradation by the proteasome, resulting in the very low levels of HDAC2 protein in the lungs of patients with severe COPD [Osoata et al. 2009a ].
Oxidative stress also activates the phosphoinositide-3-kinase (PI3K) pathway, which results in phosphorylation of serine residues and inactivation of HDAC2 [Failla et al. 2007 ]. The high level of oxidative/nitrative stress in COPD lungs, particularly as the disease progresses, may therefore result in increased tyrosine nitration, serine phosphorylation and ubiquitination, leading to impaired HDAC2 catalytic activity and a reduction in protein levels, which thereby leads to increased expression of inflammatory genes and impaired responses to corticosteroids. As discussed above there is also a reduction in HDAC2 mRNA indicating an addition reduction in transcriptional activity.
Theophylline as an HDAC activator
An attractive therapeutic option is to reverse the cause of corticosteroid resistance by inhibiting the specific molecular pathways involved. Selective activation of HDAC2 can be achieved with low concentrations of theophylline ($10 À6 M), which restores HDAC2 activity in COPD macrophages back to normal and reverses corticosteroid resistance [Cosio et al. 2004; Ito et al. 2002b ]. In cigarette smoke exposed mice, which develop corticosteroid-resistant inflammation, oral theophylline is also effective in reversing resistance and clinical trials to test this in COPD patients are currently underway. In smoking asthmatics, who are corticosteroid resistant, a low dose of theophylline appears to be effective in reversing resistance [Spears et al. 2009 ] and accelerates recovery of an acute COPD exacerbation, an effect which is accompanied by increased HDAC activity ion sputum macrophages and reduced inflammatory mediators [Cosio et al. 2009 ].
Theophylline has several molecular mechanisms of action, including phosphodiesterase inhibition and adenosine receptor antagonism at therapeutic concentrations. However, the molecular Stimulation of normal alveolar macrophages activates nuclear factor-kB (NF-kB) and other transcription factors to switch on histone acetyltransferase leading to histone acetylation and subsequently to transcription of genes encoding inflammatory proteins, such as tumour necrosis factor-a (TNF-a) and CXCL8 (IL-8). Corticosteroids reverse this by binding to glucocorticoid receptors (GR) and recruiting histone deacetylase-2 (HDAC2) This reverses the histone acetylation induced by NF-kB and switches off the activated inflammatory genes. In COPD patients, cigarette smoke activates macrophages, as in normal subjects, but oxidative stress (acting through the formation of peroxynitrite) impairs the activity of HDAC2. This amplifies the inflammatory response to NF-kB activation, but also reduces the anti-inflammatory effect of corticosteroids as HDAC2 is now unable to reverse histone acetylation. mechanism of action of theophylline in restoring HDAC2 appears to be via selective inhibition of PI3Kd, which is activated by oxidative stress in COPD patients [Marwick et al. 2009 [Marwick et al. , 2008 . This suggests that selective PI3Kd inhibitors may also be effective and these drugs are currently in clinical development for other diseases.
Since oxidative stress appears to me an important mechanism in reducing HDAC2 and leads to corticosteroid resistance, antioxidants should also be effective. In the future, novel drugs which increase HDAC2 may be developed when the molecular signaling pathways that regulate HDAC2 are better understood.
Future directions
The recognition that histone acetylation activates inflammatory genes and can be modified by antiinflammatory therapies, such as corticosteroids, suggests that it may be possible to identity novel targets that may lead to the development of novel therapies [Barnes, 2009b] . Understanding these mechanisms may also lead to the development of new treatments with the ability to reverse corticosteroid resistance in airway disease. This is already exemplified by the ability of low concentrations of theophylline to reverse corticosteroid resistance in COPD cells in vitro, smoking animals in vivo and in patients with asthma and smoking asthmatics, as discussed above.
Antioxidants
Since oxidative/nitrative stress appears to be a mechanism that can lead to corticosteroid resistance antioxidants and inhibitors of iNOS may be effective through inhibiting the generation of peroxynitrite. Currently available antioxidants, such as vitamins C and E and N-acetylcysteine, are not very potent and may not reduce oxidative stress in the lung sufficiently. Oral N-acetyl cysteine failed to reduce exacerbations or the decline in lung function in COPD patients treated with or without inhaled corticosteroids [Decramer et al. 2005] . Selective iNOS inhibitors are now in clinical development and may be effective in reducing Figure 3 . Possible mechanisms for decreased HDAC in COPD. Superoxide anions (O À 2 ) and nitric oxide (NO) generated by cigarette smoke and inflammatory cells combine to from peroxynitrite. NO production from inflammatory cells is derived from inducible NO synthase (iNOS) in response to inflammatory stimuli. Peroxynitrite nitrates histone deacetylase-2 (HDAC2) at a tyrosine (Tyr) residue within the catalytic site. This may inactivate HDAC2 and also lead to ubiquitination (Ub) of the enzyme which labels HDAC2 for degradation by the proteasome, resulting in reduced expression. Oxidative stress also activates a phosphoinositide-3-kinase (PI3K) pathway that phosphorylates (P) and inactivates HDAC2. Loss of HDAC function then results in enhanced inflammatory gene expression and blocks the anti-inflammatory action of corticosteroids. HDAC function may restored by antioxidants, iNOS inhibitors or peroxynitrite scavengers which reduce tyrosine nitration or by theophylline, curcumin or PI3K inhibitors which restore HDAC function to normal.
peroxynitrite formation [Hansel et al. 2003 ], but may not prevent the generation of peroxynitrite from NO in cigarette smoke. More potent antioxidants and peroxynitrite scavenger drugs are now in development [Kirkham and Rahman, 2006] . The transcription factor Nrf2 (nuclear factor erythroid-derived 2-related factor-2) plays a key role in the regulation of endogenous antioxidant genes and is defective in COPD patients. Several Nrf2 activators, such as sulforaphane (which occurs naturally in broccoli) and the synthetic triterpenoid 1- [2-cyano-3-,12-dioxooleana-1,9-dien-28-oyl] imidazole-methyl ester, have now been identified [Sussan et al. 2009 ].
New theophyllines?
Theophylline increases HDAC activity and expression through a mechanism that is independent of phosphodiesterase (PDE) inhibition or adenosine receptor antagonism, which together account for all of the known side effects of theophylline [Ito et al. 2002b] . This suggests that it may be possible to design related molecules that preserve the HDAC activating effect without any effects on PDE or adenosine receptors. As discussed above, low concentrations of theophylline appear to increase HDAC2 via selective and direct inhibition of oxidant-activated PI3Kd and its effects are mimicked by PI3Kd inhibitors which have been developed for other indications. Drugs that act further down the PI3Kd pathway may be similarly effective.
Curcumin
Curcumin, a polyphenol found in curry powder, also reverses corticosteroid sensitivity-induced human monocytes by oxidative stress and cigarette smoke extract by restoring HDAC2 expression to normal ]. However curcumin is very nonspecific and also inhibits HAT activity and NF-kB, making its effects difficult to interpret [Chen et al. 2007 ].
HDAC2 activators
Using high throughput screening it may be possible to identify drugs that directly activate HDAC2 [Barnes, 2005] . Several nonselective HDAC inhibitors, such as trichostatin A and valproate, have now been developed for the treatment of malignancies, but activators have so far proved to be elusive.
Concluding comments
The elucidation of HDAC2 as a critical mechanism in the regulation of inflammatory genes has identified several novel molecular targets, particularly in inflammatory diseases where corticosteroids are poorly effective due to reduced HDAC2 activity and expression. This may lead to the development of novel anti-inflammatory therapies, including drugs that are able to reverse corticosteroid resistance in diseases such as COPD, severe asthma and cystic fibrosis, which are currently difficult to manage.
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